Legal & General Group PLC Nuvation Bio Inc. Transaction History

Legal & General Group PLC

$440 Billion
Q2 2024

A detailed history of Legal & General Group PLC transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 144,893 shares of NUVB stock, worth $346,294. This represents 0.0% of its overall portfolio holdings.

Number of Shares

144,893

Previous 11,405 1170.43%

Holding current value

$346,294

Previous $41,000 931.71%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.58 - $3.69 $344,399 - $492,570	133,488 Added 1170.43%	144,893 $423,000
Q1 2024 May 14, 2024	SELL	$1.46 - $3.97 $7,568 - $20,580	-5,184 Reduced 31.25%	11,405 $41,000
Q4 2023 Feb 15, 2024	SELL	$0.96 - $1.53 $69,773 - $111,201	-72,681 Reduced 81.42%	16,589 $25,000
Q3 2023 Nov 14, 2023	SELL	$1.26 - $2.1 $2,890 - $4,817	-2,294 Reduced 2.51%	89,270 $119,000
Q2 2023 Aug 14, 2023	BUY	$1.56 - $1.84 $71,721 - $84,594	45,975 Added 100.85%	91,564 $164,000
Q1 2023 May 15, 2023	BUY	$1.6 - $2.48 $7,416 - $11,494	4,635 Added 11.32%	45,589 $75,000
Q3 2022 Nov 14, 2022	BUY	$0.29 - $4.04 $517 - $7,215	1,786 Added 4.56%	40,954 $92,000
Q2 2022 Aug 22, 2022	SELL	$3.24 - $5.85 $14,495 - $26,172	-4,474 Reduced 10.25%	39,168 $127,000
Q1 2022 May 16, 2022	SELL	$4.6 - $8.83 $197 - $379	-43 Reduced 0.1%	43,642 $230,000
Q4 2021 Feb 14, 2022	BUY	$7.75 - $10.05 $54,769 - $71,023	7,067 Added 19.3%	43,685 $371,000
Q3 2021 Nov 15, 2021	BUY	$7.78 - $10.0 $207,375 - $266,550	26,655 Added 267.54%	36,618 $365,000
Q2 2021 Aug 12, 2021	BUY	$9.22 - $14.48 $91,858 - $144,264	9,963 New	9,963 $92,000

Others Institutions Holding NUVB

# of Institutions

151

Shares Held

123M

Call Options Held

9.7K

Put Options Held

6.5K

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $519M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Nuvation Bio Inc. Transaction History